A trend toward a higher ORR was seen in patients with PD-L1+ vs. PD-L1– tumor-associated immune cells in the overall population (16.7% vs. 1.6%) and in the TNBC subgroup (22.2% vs. 2.6%) [12]. Here, CD274 is linked to neoplasm.